Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Rocket Pharmaceuticals, Inc.

RCKT ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$2.31

▲ +5.00%

Market Cap $253.58M · Vol 555.78K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$253.58M

Micro Cap

Div Yield

N/A

EPS Growth

+92.45%

YoY

RSI (14)

41.61

Momentum

Beta

0.50

vs Market

52W High

$5.45

59.63% below

52W Low

$2.17

1.38% above

Volume

555.78K

Avg 520.78K

P/B

1.37

Price-to-book

ROE

-60.27%

Return on equity

Free Float

96.84%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Rocket Pharmaceuticals, Inc. (RCKT) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RCKT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.12%

-31.04%

-30.00%

-39.21%

YTD

-34.19%

-39.21%

-86.27%

-92.14%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-223,123,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-60.27%
ROA · ROIC	-52.00% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.37
P/FCF	N/A
EPS Growth	+92.45%
Outstanding Shares	109.77M

Technical Indicators

50-Day SMA	$3.09
200-Day SMA	$3.49
RSI (14)	41.61
Beta	0.50
52-Week High	$5.45
52-Week Low	$2.17

Volume Today	555.78K
Avg Daily Volume (30D)	520.78K
Relative Volume	1.07x
Volatility (10D)	81.79
Volatility (30D)	70.24
Free Float	96.84%

Analyst Consensus

BUY

Current Price $2.31

Mean Target $8.69

52W Low$2.17 52W High$5.45

Current

Target

$2.17 $5.45

Current Analyst target

+276.08% upside potential · 14 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001T92156

ISINUS77313F1066

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.